To Heal Diabetic Foot Ulcers, A New Drug Harnesses Stem Cells Inside Us All : RushPRNews - Newswire & Global Press Release Distribution

 
Bookmark and Share

To Heal Diabetic Foot Ulcers, A New Drug Harnesses Stem Cells Inside Us All

November 12, 2009

Princeton, NJ (rushPRnews) 11/12/09 — Diabetic foot ulcers are the primary cause of hospital admissions for diabetics. Foot ulcers that heal improperly are at risk for infection, which can lead to amputation.  According to the American Diabetes Association, one in four patients with diabetic foot ulcers will eventually require lower-limb amputation.  Now science has found a way of mobilizing stem cells within the body to treat this health issue, which affects more than three million Americans annually.

Mesenchymal stem cells (MSCs), as distinct from the embryonic type, may be the key to healing diabetic foot ulcers.  These stem cells can differentiate into various cell types.  As a fetus develops, MSCs help drive its rapid initial growth; by the time we reach our teens, however, MSCs are mostly found in bone marrow.  

When wounded or burned, our skin craves MSCs, which it harbored when first growing.  In fact, recent studies show that surgically moving these cells from bone marrow onto hard-to-heal wounds accelerates healing.  

In contrast to surgically removing MSCs from bone marrow—a painful, time consuming and expensive process—a new topical drug, the novel angiotensin analog DSC127, appears to activate the mesenchymal stem cells in a patient’s body. 

“It appears that DSC127 directs MSCs to the injury site, mobilizing them to help repair wounded or burned skin, accelerate healing and reduce scar formation,” said Edward J. Quilty, Chairman & CEO of Derma Sciences Inc.  Based in Princeton, New Jersey, Derma Sciences develops, manufactures, and markets innovative wound care products.  “DSC127,” Quilty observed, “thus works as a catalyst for a stem cell treatment that is free of both the ethical controversies surrounding the medical use of fertilized embryos as well as potentially painful surgical interventions.”

Currently in a 75-patient Phase II diabetic foot ulcer clinical trial being conducted at some of the nation’s top institutions, the drug is being considered for additional indications including venous leg ulcers, arterial ulcers, pressure ulcers, thermal and chemical wounds, and scar prevention.  Pre-clinical animal studies have demonstrated the efficacy of the compound in accelerating healing and reducing scar formation. 

If DSC127 is approved for market, patients with diabetic foot ulcers may find a solution already exists within their own bodies.  For more information, visit www.dermasciences.com.

Media Contact Name: Janet Vasquez
Media Phone: 212-825-3210
Media Web Address: http://www.irgnews.com
Company Web Address: http://www.dermasciences.com
About the author:

Janet Vasquez, Director of Corporate Communications

About IRG

We are The Investor Relations Group (IRG), a full-service corporate communications firm that provides investor relations and public relations services to nano-, micro- and small-cap companies providing them with the equivalent in-house services of a large-cap company.

http://www.investorrelationsgroup.com

Click here to see all news from this author/company

Filed Under: Article-byline, BREAKING NEWS, FDA- Pharmaceutical news

RUSH PR NEWS newswire and press release services at rushprnews.com / AH Marketing ahmarketinggroup.com

Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.

Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.

Rush PR News is not the contact for material published.

RSSFeed PRESS & SOCIAL MEDIA RELEASES

Why Starting Off with VPS Hosting is a Wise Decision

London, UK 06/27/16 · You may have heard the term ‘VPS Hosting,...

FlipBelt Launches Hydration Belt for Runners and Fitness Enthusiasts

DENVER, CO 06/22/16 · FlipBelt announces new version of its wildly popular...

Kickstarter Fun: Wu & Y: Combines Art & Activewear

Brooklyn, NY 06/16/16 · Artistic Activewear Brand Raises 20K on the First...

Nursing Schools Struggle to Keep Up With Demand for Nurses

Peoria, Illinois 06/15/16 · Recent studies carried out by the Georgetown Center...

20 Dollars Discount On All PR Distribution Packages Now

San Francisco 06/14/16 · Time to share the joy again! We just...

A Look Back at RPRNmag Newsmagazine Crowdfunding Stories

San Francisco 06/09/16 · CROWDFUNDING A Look Back at Crowdfunding Campaigns: From Wood...

RPRNmag Newsmagazine Top Stories in May: Robotics & Education

San Francisco 06/07/16 · Recap Stories for the Month of MayLooking back...

Top 5 Must-Have Technologies for Startup Businesses

San Francisco 06/07/16 · Find the Secret to Making Your Small Business...

Ultraseal explains the transformation of casting impregnation at conference in Mexico

QuerĂ©taro, Mexico 06/07/16 · The transformation of casting impregnation into a two-stage,...

Diligence International Knows Latin America

Carrollton, TX 06/03/16 · As global investigators, Diligence International Group, LLC (www.digroup-us.com)...

Losode Makes The Second Round at Voom2016

LONDON, UNITED KINGDOM 06/01/16 · Losode set to disrupt the global fashion industry...

$20 Off PR Events Coupon. Publish Your Press Release Today

San Francisco 05/31/16 · RushPRNews' motto is PR Made Easy, and we are...

High-Tech Bridge Uncovers Large Number Of Fraudulent Cybersecurity Company Domains

San Francisco, CA and Geneva Switzerland 05/27/16 · Research into the proliferation of fraudulent domains affecting...